By reducing cytokine production as well as decreasing microglial activation, siRNAs that target TNF-α or NLRP3 inflammasome components, for example, have shown significant effectiveness in preclinical models of Parkinson’s and Alzheimer’s diseases. The gene discussed is NLRP3; the disease is early-onset autosomal dominant Alzheimer disease.